CYRAMZA (Eli Lilly and Company)
Welcome to the PulseAid listing for the CYRAMZA drug offered from Eli Lilly and Company. This Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC],VEGFR2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Eli Lilly and Company |
| NON-PROPRIETARY NAME: | ramucirumab |
| SUBSTANCE NAME: | RAMUCIRUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC],VEGFR2 Inhibitors [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2014-04-21 |
| END MARKETING DATE: | 0000-00-00 |
CYRAMZA HUMAN PRESCRIPTION DRUG Details:
| Item Description | CYRAMZA from Eli Lilly and Company |
| LABELER NAME: | Eli Lilly and Company |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 10(mg/mL) |
| START MARKETING DATE: | 2014-04-21 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0002-7669_82b47bfc-57e1-4299-a915-7a3003992b4b |
| PRODUCT NDC: | 0002-7669 |
| APPLICATION NUMBER: | BLA125477 |
Other RAMUCIRUMAB Pharmaceutical Manufacturers / Labelers:
